University of Miami submits ibogaine application to federal authorities

The University of Miami has transferred its investigational new drug application for ibogaine to the federal government, as announced by former President Donald Trump. This move, disclosed by Trump on Truth Social, aims to expedite the development of ibogaine as a medical treatment in the United States.

What the announcement entails

Trump revealed that the University of Miami's original 1994 ibogaine application has been handed over to the federal authorities. He described this as a significant step towards accelerating the drug's development. The announcement follows an executive order signed by Trump in April, which sought to fast-track research into psychedelic drugs, including ibogaine. This order was supported by Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, who highlighted ibogaine's potential in treating opioid addiction.

Recent research findings

According to a study published in _Nature Mental Health_ on July 24, 2025, by Stanford Medicine researchers, ibogaine shows promise in treating veterans with post-traumatic stress disorder (PTSD), anxiety, and depression, particularly when combined with magnesium to mitigate cardiac risks. The research, led by Nolan Williams, MD, involved 30 veterans and utilized electroencephalography and MRI scans to explore the neural mechanisms behind cognitive improvements. The study found that improved executive function was associated with increased theta brain wave rhythms, while reduced PTSD symptoms correlated with decreased complexity in cortical brain activity.

Why it matters

The transfer of the ibogaine application is seen as a pivotal step in potentially providing new treatment options for veterans and others suffering from serious mental health conditions. Trump's announcement underscores the ongoing efforts to enhance research collaboration between the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA), along with securing FDA guidance. The initiative aims to ensure that veterans with mental illnesses have access to innovative treatments under the "Right to Try" law.

The development marks a significant milestone in the broader movement to explore psychedelic substances for therapeutic use, particularly for conditions that have been resistant to traditional treatments.